//

Cell Genesys. Inc.

Posted Mon, 09/14/2009 - 12:23 by Zefu

Cell Genesys. Inc.

500 Forbes Blvd.
South San Francisco, CA 94080
USA
Phone: (650) 266-3000
Fax: (650) 266-3010
Email: ir@cellgenesys.com
Web Site: http://www.cellgenesys.com/

A. Company Profile

Cell Genesys (NASDAQ: CEGE) focuses on the development and commercialization of novel biological therapies for patients with cancer. The company is conducting clinical trials in multiple types of cancer utilizing its product platform technologies-GVAX cancer vaccines and oncolytic virus therapies.

B. Products

Product Pipelines
Product Indication Clinical Status
CG070 Bladder cancer Phase I
GVAX Leukemia, pancreatic cancer, and prostate cancer Phase II-III

1. CG0070

CG0070 is an oncolytic virus therapy with specificity for multiple cancers. CG0070 is an armed oncolytic virus therapy, so-named because it has been engineered to secrete GM-CSF, an immune stimulating hormone, which also serves as the adjuvant in cancer immunotherapy platform. As a result, CG0070 can potentially destroy cancer cells by two different mechanisms: direct cell killing by the virus and immune-mediated cell killing stimulated by GM-CSF.

2. GVAX

GVAX is a whole cell vaccine that is designed to stimulate an immune response against patient tumor. The vaccine are comprised of tumor cells that have been irradiated and genetically modified to secrete GMCSF (Granulocyte Macrophage Clony Stimulation Factor) an immune stimulating hormone which plays a key role in stimulating the body's immune response to vaccines. The configurations currently being evaluated are as follows: vaccines that are made with tumor cells from cancer cells lines and vaccines that are made either entirely from the patient's own tumor cells, or by mixing the patient's tumor cells with a non patient-specific GVAX product.